Haizheng Pharmaceutical (600267): Continued Improvement of Operating Efficiency+Profitability, Revitalizing New Opportunities for Established Pharmaceutical Companies
Haizheng Pharmaceutical (600267) First Coverage Report: Asset Revaluation, Reversal of Difficulties, and Steady Improvement of Profitability
Haizheng Pharmaceutical (600267): Asset revaluation, reversal of difficulties, steady improvement in profitability
Deep* Company* Haizheng Pharmaceutical (600267): Performance continues to grow, product pipeline expansion accelerates
Deep* Company* Haizheng Pharmaceutical (600267): Reached a strategic cooperation agreement with Wangshi Biotech and was entrusted with the production of the COVID-19 oral drug VV116
Haizheng Pharmaceutical (600267): The initial implementation of Haizheng Vrui Battle Investment opens up a new situation in the company's development
Haizheng Pharmaceutical (600267): Fundamentals are gradually improving, and many major products will soon be approved
Haizheng Pharmaceutical (600267): The inflection point of profit after deduction of profit turned into profit is clear
Haizheng Pharmaceutical (600267): Monoclonal monoclonal assets plan to be introduced to further implement investment and industrial integration
Haizheng Pharmaceutical Industry (600267): multiple factors drag down performance, R & D and Innovation in 2018 to promote long-term growth
Haizheng Pharmaceutical (600267): The low point has passed and an inflection point is approaching
Haizheng Pharmaceutical (600267) Update Report: Biopharmaceuticals+Small Molecule Innovative Drugs Entering Harvest Period
Haizheng Pharmaceutical Industry (600267) Quarterly report comments: biological drugs, CSO business good frequent inflection point is coming
Haizheng Pharmaceutical Co., Ltd. (600267): Hanhui Pharmaceutical opens the international CSO diabetes line to introduce war investment and accelerate research and development.
Haizheng Pharmaceutical Industry (600267) comments: the valuation of biological drugs shows that the value of CSO platform begins to reflect.
Haizheng Pharmaceutical (600267) Comment: Adalimumab production accepted, biopharmaceuticals entering harvest period
Haizheng Pharmaceutical (600267) Quarterly Report Review: Pharmaceutical sales have broken out of the trough and products under development are progressing smoothly
[Dongwu Securities] Haizheng Pharmaceutical: Pharmaceutical sales have broken out of a low point, and products under development are progressing smoothly
Haizheng Pharmaceutical (600267) Annual Report Review: Operations hit bottom and profits are expected to improve in 2016
Haizheng Pharmaceutical (600267) Review: Transformation has entered a difficult time
No Data